TIDMPOLB

RNS Number : 9515B

Poolbeg Pharma PLC

06 October 2022

Poolbeg Pharma plc

CEO Share Purchase

6 October 2022 - Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, 'Poolbeg' or the 'Company'), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, has been notified that Chief Executive Officer, Jeremy Skillington, has purchased 718,733 ordinary shares of 0.02 pence each in the Company ("Ordinary Shares") at a share price of 4.78 pence per share.

Following the purchase, Jeremy Skillington's beneficial interest in the Company is 718,733 Ordinary Shares, representing 0.14 per cent. of the total issued share capital.

Jeremy Skillington, PhD, CEO of Poolbeg Pharma, said:

"Following the significant levels of activity and excellent progress that has been made across our growing asset portfolio over recent months, I am pleased to now finally have the opportunity to purchase shares in the Company. Poolbeg is entering a very exciting phase in its development with a number of near-term value inflection points and I am confident in our potential to create future value for the Company and our shareholders through advancing and partnering our pipeline of infectious disease treatments."

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 (as implemented into English law) ("MAR").

- Ends -

Enquiries

 
  Poolbeg Pharma Plc 
   Jeremy Skillington, CEO 
   Ian O'Connell, CFO                         +44 (0) 20 7183 1499 
  finnCap Ltd (Nominated Adviser & Joint 
   Broker) 
   Geoff Nash, James Thompson, Charlie 
   Beeson, 
   Sunila de Silva (ECM), Nigel Birks         +44 (0) 20 7220 0500 
  Singer Capital Markets (Joint Broker) 
   Phil Davies, Sam Butcher                   +44 (0) 20 7496 3000 
  J&E Davy (Joint Broker) 
   Anthony Farrell, Niall Gilchrist           +353 (0) 1 679 6363 
  Instinctif Partners                         +44 (0) 20 7457 2020 
   Melanie Toyne Sewell, Rozi Morris, Tim      poolbeg@instinctif.com 
   Field

About Poolbeg Pharma

Poolbeg Pharma is a clinical stage infectious disease pharmaceutical company, with a unique capital light clinical model which aims to develop multiple products faster and more cost effectively than the conventional biotech model. The Company, headquartered in London, is led by a team with a track record of creation and delivery of shareholder value and aspires to become a "one-stop shop" for pharma and biotech seeking mid-stage products to license or acquire.

The Company is targeting the growing infectious disease market. In the wake of the COVID-19 pandemic, infectious disease has become one of the fastest growing pharma markets and is expected to exceed $250bn by 2025.

With its initial assets from Open Orphan plc , an industry leading infectious disease and human challenge trials business, Poolbeg has access to knowledge, experience, and clinical data from over 20 years of human challenge trials. The Company is using these insights to acquire new assets as well as reposition clinical stage products, reducing spend and risk. Amongst its portfolio of exciting assets, Poolbeg has a small molecule immunomodulator for severe influenza (POLB 001) which has commenced its LPS human challenge trial with initial results expected by year end 2022; a first-in-class, intranasally administered RNA-based immunotherapy for respiratory virus infections (POLB 002); and a vaccine candidate for Melioidosis (POLB 003). The Company is also developing an oral vaccine delivery platform and is progressing two artificial intelligence (AI) programmes to accelerate the power of its human challenge model data and biobank, with results from the first programme expected by year end 2022.

For more information, please go to www.poolbegpharma.com or follow us on Twitter and LinkedIn @PoolbegPharma.

Notification of transactions by Directors, Persons Discharging Managerial Responsibilities ("PDMRs") and persons closely associated with them.

 
       Details of the person discharging managerial responsibilities 
  1.    / person closely associated 
 a)    Name                               Jeremy Skillington 
      ---------------------------------  ------------------------------------- 
       Reason for the Notification 
  2. 
      ------------------------------------------------------------------------ 
 a)    Position/status                    Chief Executive Officer 
      ---------------------------------  ------------------------------------- 
 b)    Initial notification/amendment     Initial notification 
      ---------------------------------  ------------------------------------- 
       Details of the issuer, emission allowance market participant, 
  3.    auction platform, auctioneer or auction monitor 
      ------------------------------------------------------------------------ 
 a)    Name                               Poolbeg Pharma plc 
      ---------------------------------  ------------------------------------- 
 b)    LEI                                213800UZ8WJLWYHBFL52 
      ---------------------------------  ------------------------------------- 
       Details of the transaction(s): section to be repeated for (i) 
  4.    each type of instrument; (ii) each type of transaction; (iii) 
        each date; and (iv)each place where transactions have been conducted 
      ------------------------------------------------------------------------ 
 a)    Description of the                 Ordinary shares of 0.02 pence each 
        Financial instrument, 
        type of instrument 
      ---------------------------------  ------------------------------------- 
       Identification code                GB00BKPG7Z60 
      ---------------------------------  ------------------------------------- 
 b)    Nature of the Transaction          Purchase of ordinary shares 
      ---------------------------------  ------------------------------------- 
 c)    Price(s) and volume(s)              Price         Volume 
                                            4.78 pence    718,733 
                                                         -------- 
      ---------------------------------  ------------------------------------- 
 d)    Aggregated information             As above 
        - Aggregated volume 
        - Price 
      ---------------------------------  ------------------------------------- 
 e)    Date of the transaction            05/10/2022 
      ---------------------------------  ------------------------------------- 
 f)    Place of the transaction           London Stock Exchange 
      ---------------------------------  -------------------------------------

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHDGBDGLBGDGDU

(END) Dow Jones Newswires

October 06, 2022 02:00 ET (06:00 GMT)

Poolbeg Pharma (LSE:POLB)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Poolbeg Pharma Charts.
Poolbeg Pharma (LSE:POLB)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Poolbeg Pharma Charts.